Imedex® is an industry leader in providing accredited, independent continuing medical education to health care professionals.

July 25, 2015

La Jolla, CA

Scientific Agenda

Saturday, July 25, 2015

Session I: Updates in thoracic oncology: What have we learned recently?
Moderator: Ramaswamy Govindan, MD

8:30 am

Welcome and introduction

8:35 am

Pre-activity audience survey via ARS

8:40 am

Immunotherapy in NSCLC - Promises and Challenges
Edward B. Garon, MD, MS

9:00 am

Emerging options in radiotherapy
Billy W. Loo, MD, PhD

9:20 am

Locally advanced NSCLC - State of Systemic Therapy
Ramaswamy Govindan, MD

9:40 am

Next Generation Clinical Trials in NSCLC (ALCHEMIST, MASTER, NCI MATCH etc)
Gregory J. Riely, MD, PhD

10:00 am

Keynote Lecture: Targeted Therapies in Lung Cancer 2.0 – Advances and promises
Alice T. Shaw, MD, PhD

10:45 am

Post-activity audience survey via ARS

10:50 am

Break

Session II: Controversial debates in thoracic oncology
Moderator: Ramaswamy Govindan, MD

11:05 am

Pre-activity audience survey via ARS

11:10 am

Drug of choice for exon 19 del EGFR mutant NSCLC

Afatinib
H. Jack West, MD

Any EGFR TKI
Edward B. Garon, MD, MS

11:55 am

ALK positive NSCLC- front line therapy

Crizotinib
Karen L. Reckamp, MD

Ceritinib
Jonathan W. Goldman, MD

12:40 pm

Lunch

2:10 pm

Molecular profiling beyond EGFR/ALK

Not for everyone
Karen L. Reckamp, MD

Must be the standard
H. Jack West, MD

2:55 pm

Extensive stage SCLC- Thoracic Radiation

Yes
Billy W. Loo, MD, PhD

No
Jonathan W. Goldman, MD

3:40 pm

Post-activity audience survey via ARS

Session III: Challenging case presentation and discussion
Moderator: Ramaswamy Govindan, MD

3:45 pm

Pre-activity audience survey via ARS

3:50 pm

Adjuvant therapy – chemotherapy issues
Gregory J. Riely, MD, PhD

4:05 pm

Adjuvant therapy for EGFR mutant NSCLC
Ramaswamy Govindan, MD

4:20 pm

Oligo metastatic NSCLC
Jonathan W. Goldman, MD

4:35 pm

Post-activity audience survey via ARS

4:40 pm

Closing notes from Moderator

4:45 pm

Adjourn